Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...6364656667686970717273...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. (Pubmed Central) -  Mar 4, 2022   
    : Dual immune checkpoint inhibition with nivolumab and ipilimumab as well as the combination of a vascular endothelial growth factor (VEGF) inhibitor and an immune checkpoint inhibitor have shown to improve outcomes in phase III trials in comparison to sunitinib (axitinib plus pembrolizumab, axitinib plus avelumab, bevacizumab plus atezolizumab, cabozantinib plus nivolumab, lenvatinib plus pembrolizumab). However, to date, there are no head-to-head trials comparing these new combination therapies and no biomarkers are available to guide the optimal choice of first line therapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Sutent (sunitinib) / Pfizer
    Journal:  2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. (Pubmed Central) -  Mar 4, 2022   
    This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan). This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal, Checkpoint inhibition:  First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. (Pubmed Central) -  Mar 1, 2022   
    Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard of care for the treatment of advanced hepatocellular carcinoma (HCC)...Sequences starting with first-line ATEZO plus BEVA followed by 5 second-line treatments (sorafenib [SORA], lenvatinib [LENVA], regorafenib, cabozantinib, and ramucirumab) were compared...Our simulation model provides a strong rationale to support ongoing trials evaluating second-line tyrosine-kinase inhibitors after first-line ATEZO plus BEVA. Future evidence from ongoing RCTs and prospective real-world studies are needed to prove the net health benefit of sequential treatment options for advanced HCC.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Lenvatinib halts aortic aneurysm growth by restoring smooth muscle cell contractility. (Pubmed Central) -  Feb 26, 2022   
    Hence, Lenvatinib is a promising new therapy to limit aortic aneurysm expansion upon local endovascular delivery. The tyrosine kinase inhibitor was able to positively affect pathways of key relevance to human AAA disease, even in a potentially new local delivery using DEBs.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Tumor mutational burden:  Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma (clinicaltrials.gov) -  Feb 22, 2022   
    P2,  N=56, Recruiting, 
    Body composition assessment by BIA before and after lenvatinib treatment is useful in predicting prognosis in lenvatinib-treated patients with HCC. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  Lenvatinib in Locally Advanced Invasive Thyroid Cancer (clinicaltrials.gov) -  Feb 21, 2022   
    P2,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jul 2021 --> Mar 2024 | Trial primary completion date: Nov 2020 --> Sep 2023
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. (Pubmed Central) -  Feb 19, 2022   
    Early phase clinical trials, particularly with pembrolizumab plus lenvatinib (EPOC 1706), demonstrated a clear signal independent of PD-L1, and a confirmatory phase III trial of pembrolizumab plus lenvatinib is planned...Questions regarding the incorporation of immunotherapy after progression on 1L immunotherapy plus chemotherapy combinations will arise as these combinations are used more frequently, and this represents a key area of future investigation. Overall, the role of immunotherapy continues to expand in GEA, and we welcome any additional tools for this difficult-to-treat group of cancers.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Review, Journal:  New Treatments for Recurrent Uterine Cancer. (Pubmed Central) -  Feb 19, 2022   
    Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer...Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal, PD(L)-1 Biomarker, IO biomarker:  Inhibition of FGFR reactivates IFNγ signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. (Pubmed Central) -  Feb 19, 2022   
    Furthermore, inhibition of FGFR signaling by lenvatinib restored the tumor response to IFNγ stimulation in mouse and human RCC cell lines. These preclinical results reveal novel roles of tumor FGFR signaling in the regulation of cancer immunity through inhibition of the IFNγ pathway, and the inhibitory activity of lenvatinib against FGFRs likely contributes to the enhanced antitumor activity of combination treatment comprising lenvatinib plus anti-PD-1 mAb.
  • ||||||||||  paclitaxel / Generic mfg.
    Review, Journal:  Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer. (Pubmed Central) -  Feb 19, 2022   
    Prior to the recent U.S. Food and Drug Administration (FDA) approvals of immunotherapy, there had been no standard of care for women after failing front-line carboplatin and paclitaxel...Then, in September 2019, the FDA approved pembrolizumab and lenvatinib for women who are not MSI-H or are MMR-proficient...Grade 3/4 treatment-related adverse events (AEs) occurring in > 20%, including fatigue, hypertension, and gastrointestinal AEs. With supportive care, early identification, and intervention, the side effect profile was manageable, with only 21% discontinuing treatment due to AEs.